{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:48:44Z","timestamp":1789750124212,"version":"4.0.1"},"reference-count":70,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015896","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:50:12Z","timestamp":1727106612000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma"],"prefix":"10.1002","volume":"2024","author":[{"given":"Tibor A","family":"Zwimpfer","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre; Melbourne Australia"},{"name":"Gynaecological Cancer Centre; University Hospital Basel; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Ewald","sequence":"additional","affiliation":[{"name":"University Medical Library; University of Basel; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Bilir","sequence":"additional","affiliation":[{"name":"Department of Global Health; Ko\u00e7 University Graduate School of Health Sciences; Istanbul Turkey"},{"name":"Department of Gynecologic Oncology; Koc University School of Medicine; Istanbul Turkey"},{"name":"Department of Obstetrics and Gynecology; University Hospitals Schleswig-Holstein, Campus Kiel; Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madawa","family":"Jayawardana","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre; Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Appenzeller-Herzog","sequence":"additional","affiliation":[{"name":"University Medical Library; University of Basel; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bizzarri","sequence":"additional","affiliation":[{"name":"UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica; Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoia","family":"Razumova","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health; Karolinska Institutet; Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kacperczyk-Bartnik","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology; Medical University of Warsaw; Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[{"name":"Gynaecological Cancer Centre; University Hospital Basel; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Medical Oncology; Prince of Wales Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David DL","family":"Bowtell","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre; Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale W","family":"Garsed","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre; Melbourne Australia"},{"name":"Sir Peter MacCallum Department of Oncology; The University of Melbourne; Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"BritishJournal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD015896-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"7382","key":"10.1002\/14651858.CD015896-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD015896-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015896-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13643-022-02045-9","article-title":"Reducing systematic review burden using Deduklick: a novel, automated, reliable, and explainable deduplication algorithm to foster medical research","volume":"11","author":"Borissov","year":"2022","journal-title":"Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015896-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nature Reviews Cancer"},{"issue":"9","key":"10.1002\/14651858.CD015896-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/ijc.34403","article-title":"Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study","volume":"152","author":"Cabasag","year":"2023","journal-title":"International Journal of Cancer"},{"issue":"7353","key":"10.1002\/14651858.CD015896-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma [published correction appears in Nature]","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nature Communication"},{"issue":"2","key":"10.1002\/14651858.CD015896-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5195\/jmla.2020.834","article-title":"Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial","volume":"108","author":"Clark","year":"2020","journal-title":"Journal of the Medical Library Association"},{"issue":"10106","key":"10.1002\/14651858.CD015896-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1002\/14651858.CD015896-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015896-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub6","article-title":"Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer","author":"Coleridge","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015896-BIB0015|cit15","unstructured":"Covidence Veritas Health Innovation 2023"},{"issue":"4","key":"10.1002\/14651858.CD015896-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmi.2022.07.019","article-title":"How to conduct a systematic review and meta-analysis of prognostic model studies","volume":"29","author":"Damen","year":"2023","journal-title":"Clinical Microbiology and Infection"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecological Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015896-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015896-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"issue":"7035","key":"10.1002\/14651858.CD015896-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1002\/14651858.CD015896-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE Guidelines 28. Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks","volume":"121","author":"Foroutan","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD015896-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41588-022-01230-9","article-title":"The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer","volume":"54","author":"Garsed","year":"2022","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1002\/14651858.CD015896-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","article-title":"Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"160","author":"Golan","year":"2021","journal-title":"Gastroenterology"},{"issue":"25","key":"10.1002\/14651858.CD015896-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015896-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"112908","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015896-BIB0028|cit28","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2022"},{"issue":"4","key":"10.1002\/14651858.CD015896-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"280\u20136","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015896-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"PO.17.00286","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015896-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015896-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"e078384","DOI":"10.1136\/bmj-2023-078384","article-title":"Guidance on terminology, application, and reporting of citation searching: the TARCiS statement","volume":"385","author":"Hirt","year":"2024","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015896-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"issue":"9990","key":"10.1002\/14651858.CD015896-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015896-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1038\/s41467-019-11037-8","article-title":"A practical guide for mutational signature analysis in hematological malignancies","volume":"10","author":"Maura","year":"2019","journal-title":"Nature Communication"},{"issue":"12","key":"10.1002\/14651858.CD015896-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/jamaoncol.2021.4252","article-title":"Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer","volume":"7","author":"Melamed","year":"2021","journal-title":"JAMA Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015896-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1002\/14651858.CD015896-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"34","key":"10.1002\/14651858.CD015896-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015896-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nature Communication"},{"key":"10.1002\/14651858.CD015896-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015896-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"24","key":"10.1002\/14651858.CD015896-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"7553","key":"10.1002\/14651858.CD015896-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"7781","key":"10.1002\/14651858.CD015896-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1002\/14651858.CD015896-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e2200258","DOI":"10.1200\/PO.22.00258","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"Journal of Clinical Oncology Precision Oncology"},{"issue":"25","key":"10.1002\/14651858.CD015896-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015896-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015896-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Molecular Cancer Therapy"},{"key":"10.1002\/14651858.CD015896-BIB0057|cit57","unstructured":"Cancer Statistics Explorer Network Ovarian Cancer Survival Rates 2004-2020 Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=61&data_type=4&graph_type=2&compareBy=stage&chk_stage_106=106&relative_survival_interval=5&hdn_sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=1"},{"issue":"7304","key":"10.1002\/14651858.CD015896-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015896-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA-A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncology"},{"issue":"20","key":"10.1002\/14651858.CD015896-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1158\/1078-0432.CCR-21-0981","article-title":"Comparative assessment of diagnostic homologous recombination deficiency-associated mutational signatures in ovarian cancer","volume":"27","author":"Sztupinszki","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD015896-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1002\/14651858.CD015896-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub4","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","author":"Tattersall","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"15","key":"10.1002\/14651858.CD015896-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015896-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"8","key":"10.1002\/14651858.CD015896-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.3390\/ijms22084203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"International Journal of Molecular Science"},{"issue":"5","key":"10.1002\/14651858.CD015896-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s10637-017-0551-z","article-title":"A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1\/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer","volume":"36","author":"Biessen","year":"2018","journal-title":"Investigational New Drugs"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10.1002\/14651858.CD015896-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:50:15Z","timestamp":1727106615000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015896"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015896","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}